Mainz Biomed Management

Management criteria checks 0/4

Mainz Biomed's CEO is Guido Baechler, appointed in Jul 2021, has a tenure of 3.33 years. directly owns 2.94% of the company’s shares, worth $155.59K. The average tenure of the management team and the board of directors is 1.8 years and 2.9 years respectively.

Key information

Guido Baechler

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.3yrs
CEO ownership	2.9%
Management average tenure	1.8yrs
Board average tenure	2.9yrs

Recent management updates

Recent updates

CEO

Guido Baechler (59 yo)

3.3yrs

Tenure

Mr. Guido Baechler serves as Chief Executive Officer at Mainz Biomed N.V. since July 1, 2021 and has been its Executive Director since July 2021. Mr. Baechler served as Chief Executive Officer at SummerBio...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Guido Baechler	CEO & Executive Director	3.3yrs	no data	2.94% $ 155.6k
William Caragol	Chief Financial Officer	3.3yrs	no data	0.83% $ 44.0k
Christopher Von Torne	Chief Operating Officer	1.8yrs	no data	0.026% $ 1.4k
Frank Krieg-Schneider	Chief Technology Officer	1.8yrs	no data	0.046% $ 2.4k
Moritz Eidens	Chief Science Officer & Executive Director	3.2yrs	no data	4.4% $ 232.9k
Stefan Erlach	Head of Human Resources	1.8yrs	no data	no data
Philipp Freese	Chief Business Officer	1.8yrs	no data	1.41% $ 74.9k

1.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: MYNZ's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Guido Baechler	CEO & Executive Director	3.3yrs	no data	2.94% $ 155.6k
Moritz Eidens	Chief Science Officer & Executive Director	16.4yrs	no data	4.4% $ 232.9k
Hans Hekland	Independent Non-Executive Director	3yrs	no data	2.8% $ 148.2k
Gregory Tibbitts	Independent Non-Executive Director	1.9yrs	no data	0.14% $ 7.2k
Heinrich Dreismann	Independent Non-Executive Chairman	1.9yrs	no data	0.34% $ 18.2k
Soren Thestrup-Nielsen	Member of Strategic Advisory Board	3yrs	no data	no data
Michele Pedrocchi	Member of Strategic Advisory Board	2.8yrs	no data	no data
Rainer Metzger	Member of Strategic Advisory Board	2.8yrs	no data	no data
Karen Richards	Member of Strategic Advisory Board	no data	no data	no data

2.9yrs

Average Tenure

59yo

Average Age

Experienced Board: MYNZ's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Mainz Biomed Management

Management criteria checks 0/4

Key information

Recent management updates

Mainz Biomed N.V., Annual General Meeting, May 31, 2024

Mainz Biomed N.V., Annual General Meeting, Jun 28, 2023

Mainz Biomed B.V. Announces Management Changes

High number of new and inexperienced directors

Mainz Biomed B.V. Appoints Dr. Douglas Rex to its Medical Advisory Board

Mainz Biomed B.V. Appoints D. Kim Turgeon to Its Medical Advisory Board

Recent updates

Mainz Biomed N.V. has filed a Follow-on Equity Offering in the amount of $9.2 million.

New major risk - Shareholder dilution

First half 2024 earnings released: US$0.49 loss per share (vs US$1.00 loss in 1H 2023)

Mainz Biomed Reports Increased Demand for Enhanced Coloalert, Existing Partners to Transition to New Version

Mainz Biomed N.V. Announces FDA Trials in 2025

Price target decreased by 33% to US$2.00

Mainz Biomed N.V. Launches Enhanced Coloalert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Mainz Biomed N.V. Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Mainz Biomed N.V. Presents an Analysis from Its eAArly Detect Study At Digestive Disease Week

Mainz Biomed N.V., Annual General Meeting, May 31, 2024

Consensus revenue estimates fall by 48%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mainz Biomed N.V. Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Consensus revenue estimates decrease by 28%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mainz Biomed N.V. has completed a Follow-on Equity Offering.

Mainz Biomed N.V. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Mainz Biomed N.V. Presents Results of Colofuture Study

Mainz Biomed N.V. Announces Positive Topline Results from its ColoFuture Study

Mainz Biomed Announces Live Launch of ColoAlert with testDNA Laboratory in Poland

Consensus revenue estimates fall by 19%

New major risk - Revenue and earnings growth

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Mainz Biomed Announces Live Launch of ColoAlert with Marylebone Laboratory in the United Kingdom

Mainz Biomed N.V. announced that it has received $5.06 million in funding from Yorkville Advisors Global LP

Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper

Mainz Biomed N.V., Annual General Meeting, Jun 28, 2023

Mainz Biomed B.V. Launches Corporate Health Program in Germany for ColoAlert

Mainz Biomed B.V. Announces Management Changes

Mainz Biomed B.V. Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

Mainz Biomed Announces U.S. Extension of Colofuture Study to Evaluate Integration of Novel Mrna Biomarkers into Coloalert

High number of new and inexperienced directors

Mainz Biomed B.V. Appoints Dr. Douglas Rex to its Medical Advisory Board

Mainz Biomed GAAP EPS of -$0.91, revenue of $0.24M beats by $0.14M

Mainz Biomed B.V. Appoints D. Kim Turgeon to Its Medical Advisory Board

Mainz Biomed N.V. and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

Mainz Biomed stock rises 22% on launch of colorectal cancer test in Italy, UAE

High number of new and inexperienced directors

Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

Mainz Biomed B.V. Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Mainz Biomed B.V. Successfully Completes Conformity Assessment to Ivdr Achieving New Level of Eu Regulatory Compliance

Mainz Biomed B.V., Annual General Meeting, Jun 28, 2022

Mainz Biomed Provides Product Development Update on Pancalert

Mainz Biomed B.V. announced delayed 20-F filing

Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer

Mainz Biomed Completes Successful Pre-Submission Process with the U.S Fda for Coloalert’S Pivotal Clinical Trial

Mainz Biomed Provides U.S. Regulatory Review Update for Coloalert

Mainz Biomed B.V. Announces the Appointment of Dr. Rainer Metzger to Its Strategic Advisory Board

Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert

Mainz Biomed: Sharp Appreciation In Value Since IPO

Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic

No independent directors

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age